Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Heery Website

Christopher R. Heery, M.D.

Selected Publications

1)  Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Cancer Immunol. Immunother. 63: 225-34, 2014.
2)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 62: 1521-31, 2013.
3)  Gulley JL, Madan RA, Heery CR.
Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer.
Am Soc Clin Oncol Educ Book. 166-70, 2013.
4)  Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL.
Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
Semin. Oncol. 39: 296-304, 2012.
5)  Madan RA, Heery CR, Gulley JL.
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.
Oncoimmunology. 1: 1167-1168, 2012.
6)  Heery CR, Hodge JW, Gulley JL.
Combining radiation and therapeutic cancer vaccines: a synergistic approach.
Breast Cancer Management. 1: 325-335, 2012.
7)  Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Clin. Cancer Res. 17: 7164-73, 2011.
8)  Bilusic M, Heery C, Madan RA.
Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
Vaccine. 29: 6485-97, 2011.
Click Here to View Collapsed Bibliography.

This page was last updated on 2/25/2014.